M
Maximillian von Eynatten
Researcher at Boehringer Ingelheim
Publications - 3
Citations - 784
Maximillian von Eynatten is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Albuminuria & Type 2 diabetes. The author has an hindex of 3, co-authored 3 publications receiving 579 citations.
Papers
More filters
Journal ArticleDOI
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Julio Rosenstock,Vlado Perkovic,Odd Erik Johansen,Mark E. Cooper,Steven E. Kahn,Nikolaus Marx,John H. Alexander,Michael J. Pencina,Robert D. Toto,Christoph Wanner,Bernard Zinman,HJ Woerle,David Baanstra,Egon Pfarr,Sven Schnaidt,Thomas Meinicke,Jyothis T. George,Maximillian von Eynatten,Darren K. McGuire +18 more
TL;DR: Among adults with type 2 diabetes and high CV and renal risk, linagliptin added to usual care compared with placebo added tousual care resulted in a noninferior risk of a composite CV outcome over a median 2.2 years.
Journal ArticleDOI
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
Vlado Perkovic,Robert D. Toto,Mark E. Cooper,Johannes F.E. Mann,Julio Rosenstock,Darren K. McGuire,Steven E. Kahn,Nikolaus Marx,John H. Alexander,Bernard Zinman,Bernard Zinman,Egon Pfarr,Sven Schnaidt,Thomas Meinicke,Maximillian von Eynatten,Jyothis T. George,Odd Erik Johansen,Christoph Wanner +17 more
TL;DR: Across all GFR categories, in participants with type 2 diabetes and CKD and/or CV disease, there was no difference in risk for linagliptin versus placebo on CV and kidney events, and AEs were balanced among groups overall and across eGFR categories.
Journal ArticleDOI
Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Simke W. Waijer,Di Xie,Silvio E. Inzucchi,Bernard Zinman,Audrey Koitka-Weber,Audrey Koitka-Weber,Michaela Mattheus,Maximillian von Eynatten,Lesley A. Inker,Christoph Wanner,Hiddo J.L. Heerspink +10 more
TL;DR: Short‐term reduction in UACR was more common with empagliflozin and was statistically significantly associated with a decreased risk of long‐term cardiovascular and renal outcomes.